Increase in Industry Payments to Oncologists Tied to Marketing of Checkpoint Inhibitors
The mean value of payments to oncologists increased over time, as did the percentage of oncologists accepting industry payments.
The mean value of payments to oncologists increased over time, as did the percentage of oncologists accepting industry payments.
Overall survival data were available for about half of the drugs.
Registry data show significant decreases in 14-day and 3-month case-fatality rates.